['diabetic gastroparesis']
['metoclopramide nasal spray', 'placebo nasal spray']

        Inclusion Criteria:

          -  Non pregnant, non lactating female subjects between the ages of 18 and 75 years

          -  Willingness and ability to give written informed consent

          -  The ability to read, understand and speak English

          -  Prior diagnosis of Type 1 or Type 2 diabetes

          -  Diagnosis of diabetic gastroparesis with confirmation of delayed gastric emptying

          -  A mean daily gastroparesis symptom score of ≥1.4 and ≤3.5 prior to randomization

          -  Subjects of childbearing potential must agree to use contraception

          -  Willingness to discontinue current treatment for diabetic gastroparesis and to avoid
             all proscribed (excluded) medications, as specified by the protocol, for the duration
             of the study

        Exclusion Criteria:

          -  Gastric bypass, gastric banding, gastric pacemaker, post surgical causes of
             gastroparesis and disorders known to be associated with abnormal gastrointestinal
             motility

          -  A history of allergic or adverse responses, including, but not limited to, acute
             dystonic reactions and tardive dyskinesia, to metoclopramide or any comparable or
             similar product

          -  A history of, or physical findings suggestive of, tardive dyskinesia

          -  A history of epilepsy or currently using and unwilling or unable stop other drugs
             known to be associated with extrapyramidal reactions at screening

          -  A history of allergy to any of the ingredients in the study drug formulation

          -  A history of organ transplant, chronic pancreatitis, gross malabsorptive syndromes,
             celiac disease, active inflammatory bowel disease (IBD), or symptomatic irritable
             bowel syndrome (IBS)

          -  Malignancy (with the exception of treated squamous cell or basal cell carcinoma of the
             skin) currently present, initially diagnosed or recurring within five (5) years of
             screening

          -  Renal dysfunction calculated as creatinine clearance (CrCl) <40 mL/min at screening

          -  Hemoglobin A1c >11.5% at screening

          -  Subjects who are trying to conceive, are pregnant, or are lactating
      